ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
DURECT Announces Outcome of POSIMIR FDA Advisory Committee Meeting
January 19, 2020DURECT announced the U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met to discuss the Class 2 New Drug Application (NDA) resubmission for POSIMIR® (bupivacaine extended-release solution). -
Durect and Sandoz sign $293m deal to commercialise Posimir in US
May 10, 2017Durect has signed a development and commercialisation agreement with Sandoz, a division of Novartis, to develop and market Posimir (Saber-Bupivacaine) in the US.
Pharma Sources Insight January 2025
